Brain-derived neurotrophic factor serum and plasma levels in the treatment of acute schizophrenia with olanzapine or risperidone: 6-week prospective study. (3rd October 2017)

• Record Type: Journal Article
• Authors: Kudlek Mikulic, Suzan; Mihaljevic-Peles, Alma; Sagud, Marina; Bajs Janovic, Maja; Ganoci, Lana; Grubisin, Jasmina; Kuzman Rojnic, Martina; Vuksan Cusa, Bjanka; Bradaš, Zoran; Božina, Nada
• Is Part Of: Nordic journal of psychiatry. Volume 71:Number 7(2017)
• Page Start: 513
• Page End: 520
• Publication Date: 2017-10-03
• Subjects: Serum BDNF -- plasma BDNF -- schizophrenia -- olanzapine -- risperidone; Psychopharmacology -- Periodicals; Psychotherapy -- Periodicals; Psychiatry -- Periodicals; Psychiatry -- Scandinavia -- Periodicals; 616.89
• DOI: 10.1080/08039488.2017.1340518
• Languages: English
• ISSNs: 0803-9488

Abstract

Abstract: Antipsychotics have been the mainstay of the treatment of schizophrenia, and their potential role in neuroprotection could be related to brain-derived neurotrophic factor (BDNF). So far different effects on both serum and plasma levels of BDNF were reported related to the various antipsychotic treatments. Aim of this study was to investigate the influence of olanzapine or risperidone on both plasma and serum levels of BDNF in patients with acute schizophrenia. For 50 participants with acute episode of schizophrenia both plasma and serum BDNF, along with the Positive and Negative Syndrome Scale (PANSS) and the Clinical Global Impression scale, were assessed pretreatment and post treatment – after 6 weeks of either risperidone or olanzapine. Results show that a weak correlation between pretreatment plasma and serum levels of BNDF was found no longer significant after 6 weeks of treatment. Antipsychotics, olanzapine and risperidone showed no significant effect on post treatment plasma and serum levels of BDNF. Pretreatment plasma level of BDNF and PANSS positive subscale were positively correlated. Post treatment serum level of BDNF and Clinical Global Impression were negatively correlated. In conclusion, plasma and serum BDNF levels could be different markers to some extent with regard to clinical symptoms, response to therapy and outcome. The interrelation between serum and plasma BDNF should be established in further studies.